General

Cartherics welcomes Senator Michelle Ananda-Rajah to its facility

Cartherics was delighted to welcome Dr Michelle Ananda-Rajah to its facility for a tour of the company’s research, development and GMP-ready manufacturing facilities.

The visit provided an opportunity to showcase how Cartherics is advancing the development of off-the-shelf induced pluripotent stem cell (iPSC)-derived CAR-NK cell therapies for high-impact women’s diseases, including ovarian cancer and endometriosis, while […]

2026-07-26T22:48:51+10:00July 26th, 2026|General|

Cartherics recognised as Asia Pacific Emerging Leader in Allogeneic Cell Therapy

Melbourne, Australia, 1 July 2026 –   Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, has been recognised as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell & Gene Therapy Excellence Awards 2026.

Cartherics is emerging as a […]

2026-07-01T15:13:31+10:00July 1st, 2026|General|

Cartherics strengthens global IP portfolio with Japanese patent grant

Melbourne, Australia, 10 June 2026 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is pleased to announce the issuance of a patent for “Genetically modified cells and uses thereof” by the Japanese Patent Office.

This is the second granted patent in Japan […]

2026-06-10T13:37:11+10:00June 10th, 2026|General The Pipeline|

CAR-NK cell therapies for solid tumours: Closing the gap between perception and reality

By Drs Ian Nisbet & Walid Azar

As published in Pharmaphorum – 14 May 2026

Immune cell therapies have transformed the treatment of certain blood cancers over the past decade. However, when it comes to solid tumours, perceptions about their effectiveness often lag behind the emerging scientific evidence.

In particular, Chimeric Antigen Receptor – Natural Killer (CAR-NK) […]

2026-05-14T11:12:41+10:00May 14th, 2026|General The Pipeline|

World Ovarian Cancer Day Q&A: Heather Hawkins on symptoms, survival and progress

Today on World Ovarian Cancer Day, we pause to listen, reflect, and amplify the voices of those who have experienced ovarian cancer first-hand. At Cartherics, this day is a powerful reminder of why we do what we do – driving awareness and advancing new treatment options that offer real hope for women.

We’re honoured to share […]

2026-05-08T09:31:23+10:00May 8th, 2026|General|

Cartherics and Catalent Expand Commercial License Agreement

April 9 (US ET), 2026 – Melbourne, Australia, and Tampa, FL – Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership.

The companies […]

2026-04-10T07:59:09+10:00April 10th, 2026|General The Pipeline|

Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis

By Wholesale Investor

In the high-octane world of biotechnology, success is often measured by the narrowest of margins. But for Dr. Ian Nisbet, CEO of Melbourne-based Cartherics Pty Ltd, the mission is defined by a gap so large it has become a “tragic” outlier in modern medicine: the chronic underfunding of women’s health.

Ovarian cancer, often called […]

2026-04-08T11:13:36+10:00April 8th, 2026|Conferences General Investor News|

Cartherics CEO Dr Ian Nisbet presents at the Emergence Investment Conference

Cartherics is pleased to share Dr Ian Nisbet’s presentation at the Emergence Investment Conference in Sydney, where he outlined the Company’s strategy, progress and vision for transforming women’s health through pioneering cellular immunotherapies.

Speaking to an audience of investors and industry leaders, Dr Nisbet highlighted Cartherics’ unique focus on developing off-the-shelf cell therapies designed specifically to […]

2026-03-02T15:41:19+11:00March 2nd, 2026|Conferences General Investor News|

Prof. Alan Trounson to present lecture at KAUST on immune cell therapies for women’s health

Cartherics is pleased to announce that Professor Alan Trounson AO, Deputy Chair, will deliver an invited lecture at King Abdullah University of Science and Technology (KAUST) titled: A Platform Technology for Immune Targeting Cancer and Endometriosis – A Women’s Health Focus. The lecture will take place on February 4, at 10.30am (AST).

In this lecture, Professor […]

2026-02-03T10:51:29+11:00February 3rd, 2026|Conferences General|

Cartherics to present at the ANZ Biologics Festival 2026

Cartherics is pleased to announce that Dr Madeline Cao, Head of Manufacturing Development and Dr Walid Azar, Chief Scientific Officer, will present at the upcoming ANZ Biologics Festival in Melbourne, showcasing Cartherics’ progress in building a discovery-to-clinic engine for scalable, off-the-shelf cell therapies.

Dr. Cao will deliver a presentation titled, ‘Off-the-Shelf’ Immuno-Cell Therapies: Manufacturing […]

2026-02-02T11:50:48+11:00February 2nd, 2026|Conferences General|
Go to Top